Advances in managing hypertrophic cardiomyopathy

About one in 500 people has hypertrophic cardiomyopathy (HCM), a condition that causes the walls of the heart to thicken and enlarge. It’s often caused by genetic mutations and is the most common inherited form of heart disease. Contrary to popular belief, vigorous exercise appears to be safe for most people with HCM. For people with symptoms, several treatments are available, including mavacamten (Camzyos), a first-in-class medication that targets the underlying cause of HCM by inhibiting a protein that helps power heart muscle contractions.